Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST):an open-label, multicentre, randomised phase 3b trial

Autor: Silvio Danese, Severine Vermeire, Geert D'Haens, Julian Panés, Axel Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravata, Frederic Lavie, Marco Daperno, Milan Lukáš, Alessandro Armuzzi, Mark Löwenberg, Daniel R Gaya, Laurent Peyrin-Biroulet, Rodolfo Rocca, Susana Lopes, Flavio Caprioli, Sandro Ardizzone, Ana Echarri Piudo, Paolo Gionchetti, Xavier Roblin, Ursula Seidler, David Andersson, Kamal Patel, Pierre Desreumaux, Simone Saibeni, Gustav From, Miroslav Fedurco, Milos Gregus, Yoram Bouhnik, Andreas Luegering, Rocco Cosintino, Ivan Bunganic, Jaime Ramos, Mariam Aguas Peris, Olivier Dewit, Mariabeatrice Principi, Emma Wesley, Paula Lago, Stephane Nancey, María Dolores Martín Arranz, Pieter Hindryckx, Ambrogio Orlando, Andrea Geccherle, Maria Laura Annunziata, Bu'hussain Hayee, Jozef Balaz, Francisco Portela, Cyrielle Gilletta, Torsten Kucharzik, Miguel Mínguez, Javier Pérez Gisbert, Ana Gutiérrez Casbas, Edouard Louis, Marco Marino, Gareth Parkes, Fraser Cummings, Bindia Jharap, Jens Kjeldsen, Luís Correia, Paula Ministro, Matthias Ebert, Erik Hertervig, Dirk Staessen, Joris Dutré, Arnaud Colard, Graham Morrison, Henning Glerup, Jens Frederik Dahlerup, Frank Wolfhagen, Marian Batovsky, Martin Molnar, Barbora Kadleckova, Paulo Caldeira, David Laharie, Xavier Hebuterne, Bruno Bonaz, Matthieu Allez, Andreas Fischer, Joaquín Ernesto Hinojosa Del Val, Miriam Mañosa Ciria, Jose Manuel Herrera Justiniano, Charlotte Soderman, Rajiv Chandy, Craig Mowat, Peter Irving, Jan Fallingborg, Jan Matous, Tomas Douda, Romain Altwegg, Jose Manuel Benitez, María Teresa Arroyo Villarino, Jordi Guardiola Capón, Daniel Ginard Vicenc, Pieter Dewint, Sven Almer, Sebastien Kindt

Publikováno v: Danese, S, Vermeire, S, D'Haens, G, Panés, J, Dignass, A, Magro, F, Nazar, M, Le Bars, M, Lahaye, M, Ni, L, Bravata, I, Lavie, F, Daperno, M, Lukáš, M, Armuzzi, A, Löwenberg, M, Gaya, D R, Peyrin-Biroulet, L & STARDUST study group 2022, ' Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST) : an open-label, multicentre, randomised phase 3b trial ', The Lancet Gastroenterology and Hepatology, vol. 7, no. 4, pp. 294-306 . https://doi.org/10.1016/S2468-1253(21)00474-X
lancet. Gastroenterology & hepatology, 7(4), 294-306. Elsevier Limited
The Lancet Gastroenterology and Hepatology, 7(4), 294-306. Elsevier Ltd

Background: A treat-to-target strategy, in which strictly defined treatment targets facilitate decision making in clinical practice, is advocated as an optimised management approach for some chronic disorders. The aim of the STARDUST trial was to ass

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c41ea76bc7f88c535499cddcf9ba8ad
https://pure.au.dk/portal/da/publications/treat-to-target-versus-standard-of-care-for-patients-with-crohns-disease-treated-with-ustekinumab-stardust(6e02a521-a146-4afb-857c-d91bbe745a10).html